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Cancer chemotherapy is limited by the modest therapeutic index of most antineoplastic drugs. Some glucuronide prodrugs
may display selective anti-tumour activity against tumours that accumulate b-glucuronidase. We examined the toxicity and
anti-tumour activity of 9-aminocamptothecin glucuronide, a new glucuronide prodrug of 9-aminocamptothecin, to evaluate its
potential clinical utility. 9-aminocamptothecin glucuronide was 25–60 times less toxic than 9-aminocamptothecin to ﬁve
human cancer cell lines. b-glucuronidase activated 9-aminocamptothecin glucuronide to produce similar cell killing as 9-
aminocamptothecin or topotecan. The in vivo toxicity of 9-aminocamptothecin glucuronide in BALB/c mice was dose-, route-,
sex- and age-dependent. 9-aminocamptothecin glucuronide was signiﬁcantly less toxic to female than to male mice but the
difference decreased with age. 9-aminocamptothecin glucuronide and 9-aminocamptothecin produced similar inhibition
(*80%) of LS174T human colorectal carcinoma tumours. 9-aminocamptothecin glucuronide cured a high percentage of CL1-
5 human lung cancer xenografts with efﬁcacy that was similar to or greater than 9-aminocamptothecin, irinotecan and
topotecan. The potent anti-tumour activity of 9-aminocamptothecin glucuronide suggests that this prodrug should be further
evaluated for cancer treatment.
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20(S)-camptothecin, an alkaloid isolated from Camptotheca acumi-
nata (Wall et al, 1966), exhibits potent antineoplastic activity
(Giovanella et al, 1989) by inhibition of topoisomerase I (Hsiang
et al, 1985). Unfortunately, camptothecin is difﬁcult to formulate
due to its low solubility in water. In addition, its soluble sodium
salt can produce unpredictable toxicity (Gottlieb et al, 1970).
Water-soluble derivatives of camptothecin have been synthesised
to overcome these problems and two such analogues (topotecan
and irinotecan) are approved for clinical use (Coleman and Miller,
1997; Shimada, 1998). Clinical use of another analogue, 9-amino-
camptothecin (9AC), is hindered by its low solubility in water
(Herben et al, 1999) despite potent anti-tumour activity (Giovanella
et al, 1996).
Glucuronides are generally less toxic and more water soluble
than the parent compounds. These properties of glucuronides,
together with the relatively high b-glucuronidase (bG,
E.C.3.2.1.31) activities found in some cancers (Pearson et al,
1989; Albin et al, 1993), suggests that glucuronide prodrugs may
be useful for cancer treatment. Although several normal tissues
such as liver, spleen, colon and bone marrow contain high activ-
ities of bG, this enzyme is located in lysosomes (Price and
Dance, 1967) and is therefore largely inaccessible to highly hydro-
philic glucuronides which pass poorly through the cell membrane
(Haisma et al, 1992). bG, however, may be more accessible in
tumours (Bosslet et al, 1998), which combined with the acidic
pH of the interstitial space (Tannock and Rotin, 1989), could allow
preferential activation of glucuronide prodrugs in tumours. In fact,
glucuronide metabolites of alkylating agents displayed potent anti-
tumour activity in select tumour models (Connors and Whisson,
1966) but subsequent attempts to exploit differences in b-glucuro-
nidase activity between tumours and normal tissues were largely
unsuccessful for alkylating agents (Young et al, 1976). More
recently, a glucuronide prodrug of doxorubicin has shown promis-
ing activity against experimental cancers (Houba et al, 2001).
Tumour-selective antibodies have also been employed to deliver
bG to tumours in a strategy termed antibody-directed enzyme
prodrug therapy (ADEPT) (Bagshawe et al, 1988). Glucuronide
prodrugs have displayed excellent anti-tumour activity when
coupled with ADEPT (Bosslet et al, 1994), even for glucuronide
prodrugs of alkylating agents that possess no activity by themselves
(Chen et al, 1997).
We recently synthesised 9-aminocamptothecin glucuronide
(9ACG), a prodrug in which glucuronic acid is connected via a
self-immolative carbamate linker to the N9 atom of 9AC (Leu et
al, 1999). 9ACG is water soluble, stable in human serum and is
a substrate for bG (Leu et al, 1999). The aim of the present study
was to investigate the toxicity and anti-tumour activity of 9ACG to
help evaluate the potential of 9ACG as a soluble prodrug of 9AC
for cancer monotherapy and ADEPT.
MATERIALS AND METHODS
Experimental animals
Male and female BALB/c and BALB/c nu/nu mice aged 5 to 20
weeks were allowed free access to food and water. All animal
experiments were carried out with ethical committee approval.
The ethical guidelines that were followed met the standards
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Experimental Neoplasia (Workman et al, 1998).
Cell lines
LS174T colon, AGS stomach, MCF-7 breast and OVCAR-3 ovarian
human cancer cell lines were obtained from the American Type
Culture Collection (Manassas, VA, USA). CL1-5 human lung
adenocarcinoma cells (Yang et al, 1992) were kindly provided by
Dr PC Yang, Department of Internal Medicine, National Taiwan
University Hospital (Taipei, Taiwan). LS174T, CL1-5 and AGS cells
were cultured in Dulbecco’s modiﬁed Eagle’s medium (Sigma, St
Louis, MO, USA) whereas MCF-7 and OVCAR-3 cells were grown
in RPMI-1640 (Sigma, St. Louis, MO, USA) supplemented with
10 mgm l
71 bovine insulin. All media were supplemented with
10% heat-inactivated bovine calf serum, 100 U ml
71 penicillin
and 100 mgm l
71 streptomycin in a 5% CO2 humidiﬁed atmo-
sphere.
In vitro cytotoxicity
Five thousand (10000 for MCF-7) cells per well were plated in 96
well microtiter plates overnight. Graded amounts of 9AC, topote-
can, 9ACG or 9ACG plus 1 mg E coli-derived bG were added for
24 h in triplicate. The cells were then washed twice with sterile
PBS and fresh medium was added for another 24 h. Fresh medium
containing 1 mC per well [
3H]thymidine was added 16 h before the
cells were harvested on glass-ﬁbre ﬁlters and the radioactivity was
measured on a Topcount scintillation counter. The results are
expressed as % inhibition=(c.p.m.S6100)/c.p.m.C where c.p.m.i
represents counts per minute of sample (S) or untreated controls
(C).
In vivo toxicity
9ACG (10 mg ml
71 in PBS) was adjusted to pH 6.5 with sodium
carbonate immediately before administration. More than 95% of
9ACG remained in the lactone form for at least 4 h as determined
by HPLC (data not shown). 9AC was prepared as a 1 mg ml
71
suspension in Lipiodol ultra-ﬂuide (Laboratorie Guerbet, Bois
Cedex, France). Mice were i.p. injected with 50 mg kg
71 9ACG,
i.v. injected with 25 or 50 mg kg
71 9ACG or s.c. injected with
2.5 or 5 mg kg
71 9AC in pilot studies using two mice per group.
A maximum transient (572 h) weight loss of less than 25% was
considered acceptable. Six 7–8 week old mice (three males and
three females) were also i.v. injected with 50 mg kg
71 9ACG.
Prodrug toxicity was further examined in three groups of six mice
(three males and three females) at three different ages (5, 10 and 20
weeks). Mice were injected with 9ACG (50 mg kg
71, i.v.) or 9AC
(5 mg kg
71, s.c.) and body weights were followed. Initial body
weight was deﬁned as the mean value of three determinations taken
4, 2 and 0 days before drug administration.
In vivo antitumour activity
Two610
6 LS174T cells or 1610
7 CL1-5 cells were s.c. injected in
the right ﬂank of 16 week old female BALB/c nu/nu mice. Tumour
bearing mice were subdivided into groups of ﬁve to eight mice.
Therapy was initiated 10–11 days after tumour inoculation, when
the mean tumour volume was 100–200 mm
3. Mice treated with
prodrug were i.v. injected with 9ACG at the indicated doses and
times. The 9AC group was s.c. injected on the contralateral ﬂank
with 3 or 5 mg kg
71 9AC as a suspension in lipiodol. Irinotecan
(10 mg kg
71) and topotecan (1.8 mg kg
71) were i.v. injected on
the indicated days. Control mice were i.v. injected with PBS follow-
ing the corresponding 9ACG schedule. Tumour volumes were
calculated as length6width6thickness60.5 and expressed in
mm
3. Tumour growth inhibition was calculated as:
Inhibition%100 ÿ 100 
mean size of treated tumours
mean size of control tumours
Statistical analysis
Statistical signiﬁcance of differences between mean values was esti-
mated with Microsoft Excel using the independent t-test for
unequal variances.
RESULTS
In vitro cytotoxicity
Table 1 compares the in vitro cytotoxicity of topotecan, 9AC,
9ACG and 9ACG mixed with bG to ﬁve human cancer cell lines.
Topotecan and 9AC displayed similar potencies with IC50 values
ranging from 3 to 30 nM. 9ACG was 25 to 60 times less toxic than
9AC but displayed similar cytotoxicity as 9AC after the glucuronide
group was enzymatically cleaved by bG.
In vivo toxicity
A single s.c. injection of 2.5 mg kg
71 9AC suspended in lipiodol
caused minimal toxicity with 10% weight loss whereas a dose of
5m gk g
71 produced about 20% weight loss (results not shown).
Mice that were i.p. injected with 50 mg kg
71 9ACG experienced
progressive weight loss and died within 6 days (results not shown).
In contrast, all mice that were i.v. injected with 25 or 50 mg kg
71
9ACG experienced dose-dependent weight loss until day 6 followed
by rapid and complete recovery within a week. A more detailed
study of toxicity performed in 7–8 week old male and female mice
with 50 mg kg
71 9ACG (Figure 1) conﬁrmed the preliminary
results. Male mice transiently lost about 25% body mass but female
mice experienced only about 5% weight loss.
The effect of age and sex on 9ACG toxicity was further exam-
ined by injecting 5, 10 and 20-week old male and female mice
with 9AC or 9ACG. An i.v. injection of 50 mg kg
71 9ACG
produced about 25% weight loss in 5-week old male mice (Figure
2A), but only 5% weight loss in 20-week old mice (Figure 2C).
9ACG produced minimal (5%) toxicity in 5-week old female mice
(Figure 2D) and virtually no weight loss in 10 or 20-week old mice
(Figures 2E,F). Regardless of age, 5 mg kg
71 9AC was more toxic
to male mice, producing about 10% weight loss (Figures 2A,B,C)
compared with 5% weight loss in female mice (Figures 2D,E,F).
Therapy of human cancer xenografts
BALB/c nu/nu mice bearing established LS174T tumours were i.v.
injected with 50 mg kg
71 9ACG in PBS or s.c. injected with
3m gk g
71 9AC as a suspension in lipiodol. Both 9ACG and
9AC inhibited LS174T tumour growth by about 80% (Figure
3A). Neither 9ACG nor 9AC produced signiﬁcant weight loss in
this experiment (Figure 3B). To investigate the inﬂuence of dose
and schedule on the anti-tumour activity of 9ACG, BALB/c nu/
nu mice bearing LS174T xenografts were i.v. injected once with
50 mg kg
71 9ACG or three times with 10 mg kg
71 9ACG.
Tumour-bearing mice were also i.v. injected three times with
10 mg kg
71 irinotecan or s.c. injected once with 5 mg kg
71
9AC. The fractionated 9ACG schedule, despite a lower total dose,
produced similar anti-tumour activity as one bolus injection of
9ACG (Figure 3C). The anti-tumour activity produced by 9ACG
and CPT711 was similar. 9AC produced good anti-tumour activ-
ity but was unexpectedly toxic, killing three of six mice by day 8.
Although 9ACG and CPT-11 produced similar maximum weight
loss of about 20%, one of six mice died after treatment with
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71 9ACG or three fractionated doses of 10 mg kg
71
9ACG.
Intravenous administration of 50 mg kg
71 9ACG on days 10
and 20 resulted in complete regression of six of seven CL1-5
tumours (Figure 4A). The treated mice experienced 14% weight
loss after the second prodrug injection, but all the mice quickly
recovered and long-term observation (100 days after therapy) did
not reveal any signs of delayed toxicity. Figure 4B compares the
treatment of CL1-5 tumours by 9ACG, 9AC or irinotecan. 9AC
signiﬁcantly (P40.05) suppressed tumour growth but four of six
mice experienced tumour relapse within 100 days. Irinotecan
produced long-term tumour regression in two of ﬁve mice but
tumour size was not signiﬁcantly delayed as compared to PBS-trea-
ted control mice. One i.v. injection of 50 mg kg
71 9ACG
signiﬁcantly (P40.05) suppressed tumour growth; ﬁve of seven
mice were apparently cured and tumour growth was suppressed
in another mouse for over 100 days. One mouse died after prodrug
treatment indicating toxicity although the maximum mean weight
loss was only 7.5% after prodrug treatment. One of ﬁve control
tumours failed to grow in this experiment. Figure 4C compares
the treatment of CL1-5 tumours with fractionated doses of
9ACG or topotecan. Treatment with six injections of 8 mg kg
71
9ACG produced signiﬁcant (P40.05) delay of tumour growth
and tumour regressions in three of seven mice. A previously
described optimal schedule for topotecan (Zamboni et al, 1998)
displayed minimal anti-tumour activity against CL1-5 xenografts
and was highly toxic; two of six mice died and mean mouse weight
was signiﬁcantly (P40.0005) decreased as compared with control
mice. The weight of mice treated with 9ACG did not signiﬁcantly
differ from control mice in this experiment.
DISCUSSION
Glucuronide analogues of anti-neoplastic drugs offer the possibility
of increasing treatment speciﬁcity for tumours that accumulate bG
(Bosslet et al, 1998; Houba et al, 1998, 2001). Potential prodrugs
must exhibit reduced toxicity compared to the parent drug as well
as allow speciﬁc conversion to the parental drug by bG. 9ACG was
less toxic than 9AC to all the cells examined, suggesting that the
glucuronide group of 9ACG hindered diffusion of the highly lipo-
philic 9AC moiety through the cell membrane. Addition of bG,
however, increased the cytotoxicity of the prodrug to similar levels
as 9AC, showing that 9ACG was converted to parent drug. 9ACG
thus behaves as a glucuronide prodrug.
The toxicity of 9ACG in mice depended on their sex and age;
9ACG was less toxic to female and to older mice. bG is induced
in mice in the epithelial cells of the kidney proximal tubule by
androgen (Paigen, 1989). Thus, bG activity is higher in male mice
(Johnson et al, 1986). Consistent with this, a glucuronide prodrug
of doxorubicin was also more toxic to male mice (Bosslet et al,
1998). bG is not induced by androgen in humans (Paigen,
1989), suggesting that glucuronide prodrugs may not display
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Table 1 In vitro cytotoxicity of 9AC, 9ACG and topotecan. Human
cancer cells were exposed to drugs for 24 h. Results represent mean
values+s.d. of triplicate determinations
Cell line
Topotecan
IC50 (nM)
9AC
IC50 (nM)
9ACG
IC50 (nM)
9ACG+bG
a
IC50 (nM) Latency
b
LS174T 7.2+0.3 5.1+0.7 160+9.3 3.7+0.02 31
CL1-5 25+0.5 30+0.2 760+11 33+1.0 25
AGS 11+0.5 7.5+0.1 350+10 7.8+0.8 47
OVCAR-3 3.7+0.02 4.5+1.5 200+2.4 6.3+0.7 44
MCF-7 14+1.5 8.2+0.3 500+33 10.5+0.3 61
ab-glucuronidase derived from E coli (1 mg per well) was added with 9ACG.
bRatio of
IC50 values of 9ACG as compared to 9AC.
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Figure 1 Toxicity of 9ACG. A single i.v. injection of 50 mg kg
-1 9ACG
was given to male and female 7–8 weeks old BALB/c mice. Control male
and female mice were untreated. Mean weights of three mice relative to
initial body weights are shown. Signiﬁcant differences between prodrug
and control groups at weight nadirs are indicated: *P40.05. Bars, s.e.
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Figure 2 Inﬂuence of age and sex on 9ACG toxicity. Male (A–C) and
female (D–F) mice aged 5 weeks (A, D), 10 weeks (B, E) or 20 weeks
(C, F) were i.v. injected with 50 mg kg
71 9ACG or s.c. injected with
5m gk g
71 9AC. Body mass was followed and compared to non-treated
animals of the same age and sex. Mean weights of three mice relative to
initial body weights are shown. Signiﬁcant differences between drug and
control groups at weight nadirs are indicated: *P40.05; **P40.005. Bars,
s.e.
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British Journal of Cancer (2002) 86(10), 1634–1638 ã 2002 Cancer Research UKgender-related differential toxicity in cancer patients. 9ACG was
also less toxic to older mice. This was not due to differences in
topoisomerase I activity, a determinant of camptothecin cytotoxi-
city, because 9AC toxicity was independent of age (Figure 2). bG
activity may decrease with age (Traurig, 1976), suggesting that acti-
vation of 9ACG by endogenous bG may be responsible for prodrug
toxicity in young mice. The high toxicity of 9ACG after i.p. admin-
istration demonstrated that prodrug toxicity also depended on the
route of administration. The mechanism of increased prodrug toxi-
city after i.p. injection is currently unknown.
9ACG displayed good anti-tumour activity against LS174T
human colon cancer xenografts in nude mice with acceptable levels
of toxicity. Treatment of tumour-bearing mice with 9ACG
produced similar inhibition of tumour growth as irinotecan. In
addition, 9ACG was equally effective but produced less toxicity
than 9AC. 9ACG was even more effective against CL1-5 human
lung adenocarcinoma tumours. 9ACG cured 70–85% of mice with
established CL1-5 tumours. 9ACG appeared to be more effective
than 9AC or topotecan against CL1-5 tumours. Topotecan
produced poor anti-tumour activity at an optimal dose schedule
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Figure 3 Anti-tumour activity of 9ACG against LS174T xenografts. (A,
B) BALB/c nu/nu mice bearing LS174T tumours were i.v. injected with
PBS, i.v. injected with 50 mg kg
71 9ACG or s.c. injected with 3 mg kg
71
9AC in Lipiodol on day 10. Mean tumour sizes (A) and weights (B)o f
six mice relative to mean values at the initiation of therapy (day 10) are
shown. The mean size of drug-treated (9AC and 9ACG) tumours was sig-
niﬁcantly (P40.05) smaller than control tumours after day 13. (C) BALB/c
nu/nu mice bearing LS174T tumours were untreated, i.v. injected with
50 mg kg
71 9ACG or s.c. injected with 5 mg kg
71 9AC in Lipiodol on
day 10, or i.v. injected with 10 mg kg
71 9ACG or irinotecan on days 10,
12 and 14. Results represent mean tumour size of 7–8 mice relative to
mean tumour size on day 10. The mean size of drug-treated (9AC,
9ACG and irinotecan) tumours was signiﬁcantly (P40.05) smaller than
control tumours after day 12. Bars, s.e.
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Figure 4 Anti-tumour activity of 9ACG against CL1-5 human lung ade-
nocarcinoma xenografts. (A) BALB/c nu/nu mice implanted with CL1-5 tu-
mour cells on day 0 were i.v. injected with PBS (solid lines) or 50 mg kg
71
9ACG (dashed lines) on days 10 and 20. Results show the tumour sizes of
individual mice. Mean body weights of control or 9ACG-treated mice are
shown relative to mean weights on day 5. Bars, s.e. (B) Nude mice im-
planted with CL1-5 cells on day 0 were i.v. injected with PBS (PBS) or
50 mg kg
71 9ACG (9ACG) on day 10, s.c. injected with 3 mg kg
71
9AC in Lipiodol on day 10 (9AC), or i.v. injected with 10 mg kg
71 irinote-
can on days 10, 12 and 14 (CPT-11). The ratio of long-term survivors
(4120 days tumour-free) in each group is indicated. (C) Nude mice im-
planted with CL1-5 cells on day 0 received i.v. injections of PBS (PBS) or
8m gk g
71 9ACG (9ACG) on days 11, 13, 15, 24, 26 and 28 or
1.8 mg kg
71 topotecan on days 11, 12, 13, 14 and 15 (topotecan). Mean
body weights of the PBS, 9ACG or topotecan treated mice are shown re-
lative to mean weights on day 8. Signiﬁcant differences between the mean
weight of mice treated with topotecan or PBS are indicated: *P40.05;
**P40.0005. Error bars are not shown for clarity.
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anti-tumour activity of 9ACG to CL1-5 tumours compared with
LS174T tumours could not be predicted by the in vitro sensitivity
of these tumour cells to 9AC or 9ACG (Table 1), indicating that
other factors, such as local in vivo tumour pH or bG levels are
likely to be important determinants of tumour sensitivity to 9ACG.
9ACG was originally synthesised as a prodrug for antibody-
directed enzyme prodrug therapy (ADEPT). In this treatment strat-
egy, prodrugs are selectively activated at tumour cells that have
been pre-targeted with antibody-enzyme conjugates (immunoen-
zymes). The ﬁnding that 9ACG produced anti-tumour activity
without the need for immunoenzyme targeting suggests that sufﬁ-
cient bG is present at tumours to convert 9ACG to 9AC. This
contrasts with a glucuronide prodrug of p-hydroxyaniline mustard
(BHAMG), which only displays anti-tumour activity when tumours
are pre-targeted with bG immunoenzymes (Chen et al, 1997).
Some tumours express high levels of bG (Pearson et al, 1989; Albin
et al, 1993) and bG may also be secreted by monocytes and gran-
ulocytes in necrotic areas of tumours (Bosslet et al, 1998).
Extracellular bG effectively activated a glucuronide prodrug of
doxorubicin in solid tumours (Bosslet et al, 1998), suggesting that
a similar mechanism may be responsible for the in vivo activity of
9ACG. Because p-hydroxyaniline mustard is about 1000 times less
cytotoxic than 9AC, it is likely that insufﬁcient BHAMG is acti-
vated by endogenous bG to produce anti-tumour activity.
In summary, the toxicity of 9ACG in mice depended on sex,
age, dose and route of administration. 9ACG displayed excellent
anti-tumour activity against established human lung xenografts.
The potent anti-tumour activity of 9ACG together with its high
water solubility and stability (Leu et al, 1999) and potential
tumour selectivity suggest that this prodrug shows promise for
cancer therapy.
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